This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Psoriasis  • Dermatology, Other  • Alert me on articles by topic

Anti–Tumor Necrosis Factor Therapy in Psoriatic Arthritis and Psoriasis

Giampiero Girolomoni, MD; Damiano Abeni, MD, MPH

Arch Dermatol. 2001;137:784-785.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ
Lancet. 2000;356:385-390

Tumor necrosis factor (TNF-) may play an important role in the pathogenesis of psoriasis and other inflammatory skin disorders.^1-3 Recently, 2 types of TNF blockers have become available for clinical use: a soluble receptor (etanercept) and an anti–TNF- monoclonal antibody (infliximab). Etanercept is a genetically engineered fusion protein consisting of 2 identical chains of the recombinant extracellular human TNF-receptor p75 monomer fused with the Fc domain of human IgG1, and is given subcutaneously twice a week.⁴ Infliximab has the variable region of a murine antibody grafted to the constant region of a human antibody, and is administered intravenously every 4 or 8 weeks.⁵

The objective of this study was to evaluate the efficacy and safety . . . [Full Text of this Article]

Editors' Comment

Istituto Dermopatico dell'Immacolata
Via Monti di Creta 104
00167 Rome, Italy